Event Description
Please note: This event is online only.
(Please contact organizer for Zoom link and ID)
Topic
Esketamine Nasal Spray in MDD: Clinical Data From Two Development Programs
Presented By
Carla M. Canuso, MD, vice president, Neuroscience Clinical Development, Janssen Research & Development
Learning Objectives
- Discuss the pivotal and supportive clinical data leading to the FDA approval of esketamine nasal spray for the treatment of adult patients with treatment-resistant depression and those with major depressive disorder with acute suicidal ideation or behavior
- Apply the appropriate risk mitigations required to ensure safe use of esketamine nasal spray
- Participants will describe additional post-hoc analyses that have been conducted to further inform the clinical use of esketamine
|